

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
**(Under 37 CFR 1.97(b) or 1.97(c))**

Docket No.  
 17758 (PC27531A)

In Re Application Of: Roberto Tonani, et al.

MAR 07 2005

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/522,250	January 25, 2005	Unassigned	23389	Unassigned	Unassigned

Title:

**CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS**

Address to:

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

**37 CFR 1.97(b)**

- The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

**37 CFR 1.97(c)**

- The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

the statement specified in 37 CFR 1.97(e);

OR

the fee set forth in 37 CFR 1.17(p).

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
17758 (PC27531A)

In Re Application: **Roberto Tonani, et al.**

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/522,250	January 25, 2005	Unassigned	23389	Unassigned	Unassigned

Title:

**CONDENSED HETEROCYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS**

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

A check in the amount of \_\_\_\_\_ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below.

Charge the amount of \_\_\_\_\_

Credit any overpayment.

Charge any additional fee required.

Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

March 3, 2005

(Date)




Signature of Person Mailing Correspondence

Peter I. Bernstein

Typed or Printed Name of Person Mailing Certificate

\*This certificate may only be used if paying by deposit account.



Signature

Dated: March 3, 2005

**Peter I. Bernstein**

Registration No. 43,497

**Scully, Scott, Murphy & Presser**

**400 Garden City Plaza-Suite 300**

**Garden City, New York 11530**

**516-742-4343**

**PIB:dg**

**CC:**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Roberto Tonani, et al.      **Examiner:** Unassigned  
**Serial No.:** 10/522,250      **Art Unit:** Unassigned  
**Filed:** January 25, 2005      **Docket:** 17758 (PC27531A)  
**For:** CONDENSED HETEROCYCLIC  
PYRAZOLE DERIVATIVES AS  
KINASE INHIBITORS      **Dated:** March 3, 2005

**Confirmation No.:** Unassigned

Mail Stop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.


1. Elnagdi M.H. et al., "The Reaction of Phenacyl Malononitrile with Hydrazines: Synthesis of New Pyridazinones and Pyrazolo[1,5- $\alpha$ ] Pyrimidines", *Gazzetta Chimica Italiana* 127:791-794 (1997), XP009018422;
2. Sherif S.M. et al., "Syntheses with Heterocyclic  $\beta$ -Enaminonitriles: An Expeditious Synthetic Approach to Polyfunctionally Substituted 5-Phenyl-Suffonylthiophenes and their Fused Derivatives", *Monatshefte für Chemie* 128:687-696 (1997), XP009018423;

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Dated: March 3, 2005

  
Peter I. Bernstein

3. Abdel Fattah Ali Harb, "Nitriles in Heterocyclic Synthesis: Novel Routus to Cyclopentenothienopyridines, Cyclopentenothieno-Pyrimidenes and Cyclopentenopyrrolopyrazoles", *Egyptian Journal of Pharmaceutical Sciences* 33(1-2):283-292 (1992); and
4. Abdelrazek F.M. et al., "Nitriles in Heterocyclic Synthesis. A Novel Synthesis of 4-Phenacylpyrazole and Pyrrolo[2,3-c]Pyrazole", *Synthesis* 74-75 (1986), XP-001155261.

The references were cited in a Search Report dated November 5, 2003 received from the European Patent Office. Applicants are submitting copies of the above-cited references, together with a copy of the Search Report. The relevance of the above-identified references has been described in the Search Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. §1.97(b), no statement or fee is required.

Respectfully submitted,  
  
Peter I. Bernstein  
Registration No. 43,497

Scully, Scott, Murphy & Presser  
400 Garden City Plaza-Suite 300  
Garden City, New York 11530  
(516) 742-4343

PIB:dg

Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (REV. 7-80) PATENT AND TRADEMARK OFFICE		Atty. Docket No. (Optional) 17758 (PC27531A)		Application Number 10/522,250			
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		Applicant(s) Roberto Tonani, et al.					
		Filing Date January 25, 2005		Group Art Unit Unassigned			
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
<b>U.S. PATENT APPLICATION PUBLICATIONS</b>							
EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
	AB						
	AC						
<b>FOREIGN PATENT DOCUMENTS</b>							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES
<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
/K.B./		Elnagdi M.H. et al., "The Reaction of Phenacyl Malononitrile with Hydrazines: Synthesis of New Pyridazinones and Pyrazolo[1,5-a] Pyrimidines", <i>Gazzetta Chimica Italiana</i> 127:791-794 (1997), XP009018422					
/K.B./		Sherif S.M. et al., "Syntheses with Heterocyclic $\beta$ -Enaminonitriles: An Expeditious Synthetic Approach to Polyfunctionally Substituted 5-Phenyl-Sulfonylthiophenes and their Fused Derivatives", <i>Monatshefte für Chemie</i> 128:687-696 (1997), XP009018423					
/K.B./		Abdel Fattah Ali Harb, "Nitriles in Heterocyclic Synthesis: Novel Routus to Cyclopentenothienopyridines, Cyclopentenothieno-Pyrimidenes and Cyclopentenopyrrolopyrazoles", <i>Egyptian Journal of Pharmaceutical Sciences</i> 33(1-2):283-292 (1992)					
/K.B./		Abdelrazek F.M. et al., "Nitriles in Heterocyclic Synthesis. A Novel Synthesis of 4-Phenacylpyrazole and Pyrrolo[2,3-c]Pyrazole", <i>Synthesis</i> 74-75 (1986), XP-001155261					
EXAMINER		/Kristin Bianchi/		DATE CONSIDERED		08/28/2008	
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							